Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiography, Dual-Energy Scanned Projection | 1 | 2018 | 5 | 0.680 |
Why?
|
| Practice Management, Medical | 1 | 2018 | 9 | 0.670 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 871 | 0.650 |
Why?
|
| Hearing Loss, Sensorineural | 3 | 2017 | 20 | 0.390 |
Why?
|
| Intracranial Hypertension | 2 | 2018 | 20 | 0.280 |
Why?
|
| Ear, Inner | 2 | 2017 | 9 | 0.270 |
Why?
|
| Temporal Bone | 2 | 2013 | 17 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 1219 | 0.220 |
Why?
|
| DiGeorge Syndrome | 2 | 2012 | 11 | 0.220 |
Why?
|
| Workflow | 1 | 2018 | 20 | 0.170 |
Why?
|
| Subdural Effusion | 1 | 2018 | 5 | 0.170 |
Why?
|
| Papilledema | 1 | 2018 | 12 | 0.170 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 40 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 1 | 2018 | 13 | 0.160 |
Why?
|
| Orbit | 1 | 2018 | 17 | 0.160 |
Why?
|
| Software | 1 | 2018 | 110 | 0.160 |
Why?
|
| Cerebellopontine Angle | 1 | 2017 | 3 | 0.150 |
Why?
|
| Cerebellar Diseases | 1 | 2017 | 4 | 0.150 |
Why?
|
| Labyrinth Diseases | 1 | 2017 | 5 | 0.150 |
Why?
|
| Decision Making | 1 | 2018 | 180 | 0.140 |
Why?
|
| Accidental Falls | 1 | 2018 | 207 | 0.140 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 11 | 0.140 |
Why?
|
| Huntington Disease | 1 | 2016 | 14 | 0.140 |
Why?
|
| Child | 7 | 2018 | 2221 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2018 | 307 | 0.140 |
Why?
|
| Humans | 13 | 2018 | 29220 | 0.120 |
Why?
|
| Ear | 1 | 2013 | 18 | 0.120 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2013 | 8 | 0.110 |
Why?
|
| Exanthema | 1 | 2013 | 21 | 0.110 |
Why?
|
| Corpus Callosum | 1 | 2012 | 13 | 0.110 |
Why?
|
| Aspartic Acid | 1 | 2012 | 13 | 0.110 |
Why?
|
| Dipeptides | 1 | 2012 | 9 | 0.110 |
Why?
|
| Brain Neoplasms | 2 | 2016 | 587 | 0.110 |
Why?
|
| Osteoclasts | 1 | 2012 | 22 | 0.110 |
Why?
|
| Child, Preschool | 4 | 2018 | 1168 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2013 | 167 | 0.110 |
Why?
|
| Prefrontal Cortex | 1 | 2012 | 69 | 0.100 |
Why?
|
| Medulloblastoma | 1 | 2010 | 7 | 0.100 |
Why?
|
| Cerebellar Neoplasms | 1 | 2010 | 11 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2010 | 74 | 0.090 |
Why?
|
| Medical Records | 1 | 2010 | 68 | 0.090 |
Why?
|
| Angiotensin I | 1 | 2012 | 262 | 0.090 |
Why?
|
| Radiology | 1 | 2010 | 37 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 301 | 0.090 |
Why?
|
| Male | 9 | 2018 | 17876 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2012 | 423 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2012 | 390 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 1079 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2018 | 3122 | 0.080 |
Why?
|
| Infant | 3 | 2018 | 973 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 441 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 546 | 0.080 |
Why?
|
| Female | 8 | 2018 | 18241 | 0.070 |
Why?
|
| Age Factors | 2 | 2018 | 1110 | 0.050 |
Why?
|
| Adolescent | 3 | 2013 | 3265 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2018 | 603 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 53 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 56 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2016 | 60 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 163 | 0.030 |
Why?
|
| Rickettsia rickettsii | 1 | 2013 | 3 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2013 | 78 | 0.030 |
Why?
|
| Acyltransferases | 1 | 2012 | 16 | 0.030 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2012 | 14 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 454 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 104 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2012 | 12 | 0.030 |
Why?
|
| Protons | 1 | 2012 | 23 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2012 | 71 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 81 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 113 | 0.030 |
Why?
|
| Organ Size | 1 | 2012 | 196 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 103 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 114 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 293 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2012 | 276 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 199 | 0.020 |
Why?
|
| Proteins | 1 | 2012 | 140 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 632 | 0.020 |
Why?
|
| Craniopharyngioma | 1 | 2010 | 8 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 104 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 379 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2010 | 37 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 33 | 0.020 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 17 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2012 | 256 | 0.020 |
Why?
|
| Peer Review, Health Care | 1 | 2010 | 4 | 0.020 |
Why?
|
| Astrocytoma | 1 | 2010 | 30 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 681 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 860 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 573 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 1366 | 0.020 |
Why?
|
| Middle Aged | 2 | 2012 | 10872 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 2372 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 1695 | 0.020 |
Why?
|
| Animals | 1 | 2012 | 7302 | 0.010 |
Why?
|
| Aged | 1 | 2012 | 9515 | 0.010 |
Why?
|
| Adult | 1 | 2010 | 8468 | 0.010 |
Why?
|